However, synthetically lethal therapies are vulnerable to resistance to either drug rendering the combination ineffective, as demonstrated by development of resistance to cancer therapies utilising synthetic lethal interactions between BRCA2 mutants and PARP inhibitors or cisplatin through secondary BRCA2 mutation [282,283]. Here, BRCA2 is linked to cancer.